Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors

NCT03700294 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.

NCT NCT03700294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03700294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors
Lead sponsor
ADC Therapeutics S.A.
Phase
Phase 1
Overall status
Terminated
Start date
December 21, 2018
Completion date
December 11, 2019
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors